In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Pacific Biosciences of California Inc’s stock clocked out at $1.5, up 2.04% from its previous closing price of $1.47. In other words, the price has increased by $2.04 from its previous closing price. On the day, 3.57 million shares were traded. PACB stock price reached its highest trading level at $1.5001 during the session, while it also had its lowest trading level at $1.4501.
Ratios:
To gain a deeper understanding of PACB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.87 and its Current Ratio is at 6.68. In the meantime, Its Debt-to-Equity ratio is 7.63 whereas as Long-Term Debt/Eq ratio is at 7.60.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 19 ’25 when Farmer Michele sold 5,195 shares for $1.00 per share. The transaction valued at 5,200 led to the insider holds 269,259 shares of the business.
HENRY CHRISTIAN O sold 12,497 shares of PACB for $17,583 on Mar 03 ’25. The insider now owns 2,225,357 shares after completing the transaction at $1.41 per share. On Mar 03 ’25, another insider, Van Oene Mark, who serves as the insider of the company, sold 6,486 shares for $1.41 each. As a result, the insider received 9,126 and left with 1,497,695 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 450127488 and an Enterprise Value of 731105984. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.95 while its Price-to-Book (P/B) ratio in mrq is 4.91. Its current Enterprise Value per Revenue stands at 4.799 whereas that against EBITDA is -3.056.
Stock Price History:
The Beta on a monthly basis for PACB is 2.15, which has changed by 0.15384614 over the last 52 weeks, in comparison to a change of 0.10500872 over the same period for the S&P500. Over the past 52 weeks, PACB has reached a high of $2.72, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is 29.69%, while the 200-Day Moving Average is calculated to be -3.82%.
Shares Statistics:
It appears that PACB traded 9.40M shares on average per day over the past three months and 11197040 shares per day over the past ten days. A total of 300.04M shares are outstanding, with a floating share count of 264.16M. Insiders hold about 11.97% of the company’s shares, while institutions hold 65.85% stake in the company. Shares short for PACB as of 1749772800 were 39640882 with a Short Ratio of 4.22, compared to 1747267200 on 56947935. Therefore, it implies a Short% of Shares Outstanding of 39640882 and a Short% of Float of 15.03.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are keenly observing as 10.0 analysts analyze and rate the current performance of Pacific Biosciences of California Inc (PACB) in the stock market.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.13 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.58 and -$0.73 for the fiscal current year, implying an average EPS of -$0.64. EPS for the following year is -$0.52, with 11.0 analysts recommending between -$0.38 and -$0.71.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $36.45M. It ranges from a high estimate of $37.3M to a low estimate of $34M. As of the current estimate, Pacific Biosciences of California Inc’s year-ago sales were $36.01MFor the next quarter, 9 analysts are estimating revenue of $39.75M. There is a high estimate of $42M for the next quarter, whereas the lowest estimate is $37.9M.
A total of 10 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $160.2M, while the lowest revenue estimate was $151.49M, resulting in an average revenue estimate of $156.14M. In the same quarter a year ago, actual revenue was $154.01MBased on 11 analysts’ estimates, the company’s revenue will be $185.15M in the next fiscal year. The high estimate is $200.8M and the low estimate is $164.53M.
